Effect of the APOE promoter polymorphisms on cerebral amyloid peptide deposition in Alzheimer's disease

Lancet

Volumn 357, Issue 9256, 2001, Pages 608-609

  Lambert, J C ^a   Mann, D ^b   Goumidi, L ^d   Harris, J ^a   Amouyel, P ^d   Iwatsubo, T ^c   Lendon, C ^a   Chartier Harlin, M C ^d  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c UNIVERSITY OF TOKYO   (Japan)

^d INSTITUT PASTEUR DE LILLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; BRAIN PEPTIDE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN REGION; FEMALE; GENOTYPE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN CONTENT; PROTEIN POLYMORPHISM;

EID: 0035941738     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)04063-0     Document Type: Article

References (5)

1. Preferential deposition of amyloid beta protein (Abeta) in the form Abeta40 in Alzheimer's disease is associated with a gene dosage effect of the apolipoprotein E E4 allele
2. Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer's disease model
3. A polymorphism in the regulatory region of APOE associated with risk for Alzheimer's dementia
4. APOE polymorphisms in Alzheimer's disease
5. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: A meta-analysis